Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 2
1992 2
1995 2
1996 1
1997 2
1998 6
1999 4
2000 2
2001 5
2002 1
2003 3
2004 3
2005 7
2006 2
2007 9
2008 2
2009 9
2010 6
2011 6
2012 6
2013 5
2014 2
2015 3
2016 5
2017 2
2018 2
2019 1
2020 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

96 results
Results by year
Filters applied: . Clear all
Page 1
Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection.
Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, Bedrosian I, Hobbs BP, DeSnyder SM, Hwang RF, Adrada BE, Shaitelman SF, Chavez-MacGregor M, Smith BD, Candelaria RP, Babiera GV, Dogan BE, Santiago L, Hunt KK, Kuerer HM. Caudle AS, et al. Among authors: gilcrease mz. J Clin Oncol. 2016 Apr 1;34(10):1072-8. doi: 10.1200/JCO.2015.64.0094. Epub 2016 Jan 25. J Clin Oncol. 2016. PMID: 26811528 Free PMC article.
Imaging features of triple-negative breast cancers according to androgen receptor status.
Candelaria RP, Adrada BE, Wei W, Thompson AM, Santiago L, Lane DL, Huang ML, Arribas EM, Rauch GM, Symmans WF, Gilcrease MZ, Huo L, Lim B, Ueno NT, Moulder SL, Yang WT. Candelaria RP, et al. Among authors: gilcrease mz. Eur J Radiol. 2019 May;114:167-174. doi: 10.1016/j.ejrad.2019.03.017. Epub 2019 Mar 21. Eur J Radiol. 2019. PMID: 31005169 Free PMC article.
Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.
Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL 3rd, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL. Basho RK, et al. Among authors: gilcrease m. JAMA Oncol. 2017 Apr 1;3(4):509-515. doi: 10.1001/jamaoncol.2016.5281. JAMA Oncol. 2017. PMID: 27893038 Clinical Trial.
A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy.
Kuerer HM, Rauch GM, Krishnamurthy S, Adrada BE, Caudle AS, DeSnyder SM, Black DM, Santiago L, Hobbs BP, Lucci A Jr, Gilcrease M, Hwang RF, Candelaria RP, Chavez-MacGregor M, Smith BD, Arribas E, Moseley T, Teshome M, Miggins MV, Valero V, Hunt KK, Yang WT. Kuerer HM, et al. Among authors: gilcrease m. Ann Surg. 2018 May;267(5):946-951. doi: 10.1097/SLA.0000000000002313. Ann Surg. 2018. PMID: 28549010 Free PMC article. Clinical Trial.
Integrin signaling in epithelial cells.
Gilcrease MZ. Gilcrease MZ. Cancer Lett. 2007 Mar 8;247(1):1-25. doi: 10.1016/j.canlet.2006.03.031. Epub 2006 May 24. Cancer Lett. 2007. PMID: 16725254 Review.
Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors.
Guo H, Ding Q, Gong Y, Gilcrease MZ, Zhao M, Zhao J, Sui D, Wu Y, Chen H, Liu H, Zhang J, Resetkova E, Moulder SL, Wang WL, Huo L. Guo H, et al. Among authors: gilcrease mz. Breast Cancer Res. 2020 Jun 23;22(1):69. doi: 10.1186/s13058-020-01303-9. Breast Cancer Res. 2020. PMID: 32576238 Free PMC article.
Role of RPL39 in Metaplastic Breast Cancer.
Dave B, Gonzalez DD, Liu ZB, Li X, Wong H, Granados S, Ezzedine NE, Sieglaff DH, Ensor JE, Miller KD, Radovich M, KarinaEtrovic A, Gross SS, Elemento O, Mills GB, Gilcrease MZ, Chang JC. Dave B, et al. Among authors: gilcrease mz. J Natl Cancer Inst. 2016 Dec 31;109(6):djw292. doi: 10.1093/jnci/djw292. Print 2017 Jun. J Natl Cancer Inst. 2016. PMID: 28040796 Free PMC article.
Transection of Radioactive Seeds in Breast Specimens.
Gilcrease MZ, Dogan BE, Black DM, Contreras A, Dryden MJ, Jimenez SM. Gilcrease MZ, et al. Am J Surg Pathol. 2016 Oct;40(10):1375-9. doi: 10.1097/PAS.0000000000000682. Am J Surg Pathol. 2016. PMID: 27627744
Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer.
Basho RK, Yam C, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Hong D, Kurzrock R, Hortobagyi GN, Janku F, Moulder SL. Basho RK, et al. Among authors: gilcrease m. Oncologist. 2018 Nov;23(11):1300-1309. doi: 10.1634/theoncologist.2017-0498. Epub 2018 Aug 23. Oncologist. 2018. PMID: 30139837 Free PMC article.
96 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page